Administering purine analogs to patients with SBLPN, where efficacy is limited, or delaying appropriate therapy in classic HCL can result in prolonged cytopenias, recurrent infections, drug-related toxicities, disease progression, and missed opportunities for targeted interventions such as BRAF inhibitors. The gene discussed is BRAF; the disease is hairy cell leukemia.